Experienced in Hyperhidrosis

Masahiro Takada

Hirakata, JP 
Experienced in Hyperhidrosis
Hirakata, JP 
OverviewLocationsClinical Research

Overview

Masahiro Takada practices in Hirakata, Japan. Mr. Takada is rated as an Experienced expert by MediFind in the treatment of Hyperhidrosis. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Cerebral Hypoxia, and Pustules.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hyperhidrosis.

Gender
Male

Locations

Hirakata, Japan
Other Locations
Kyoto, Japan
Nagoya, 4668550, Japan
Kawahara, 6068507, Japan
Tokyo, Japan
Kashiwa, 2778583, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Drug
Study Drug: Anti PD-1 Antibody
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

46 Total Publications

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: June 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Takada's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile